Sanofi

Sanofi and SK Bioscience expand collaboration to develop next-gen PCVs for pediatric and adult populations, co-funding R&D. Sanofi pays €50m upfront, with success-dependent milestone payments. Sanofi to commercialize globally except South Korea, where SK Bioscience has exclusivity. Phase III testing of PCV21 vaccine begins next week. Despite vaccination programs, invasive pneumococcal disease persists, driving market growth.

Sanofi and SK bioscience expand collaboration to develop next-gen pneumococcal conjugate vaccines (PCVs), initiating phase 3 for PCV21, the first 21-valent PCV candidate in infants & toddlers. The partnership aims to address unmet needs in invasive pneumococcal disease, leveraging both companies' expertise and capabilities.

Tennessee universities, like Vanderbilt and Meharry Medical College, drive innovation with 100 licenses granted in 2023 and partnerships with Sanofi and Oracle. The Bayh-Dole Act supports public-private partnerships, enabling $888 million in bioscience R&D in 2020. IP protection is crucial for innovation, but misuse of the 'march-in' provision could harm research, jobs, and medical advancements. Lawmakers like Sen. Marsha Blackburn support innovation, emphasizing the need for continued IP protection.

Novo Holdings completes $16.5B Catalent Pharma Solutions buyout. Merck pays $112M upfront for obesity pill. Ottimo Pharma raises $140M for cancer therapy. Novo Nordisk invests $1.2B in Denmark factory. Angitia Biopharmaceuticals raises $120M for musculoskeletal candidates. Novartis closes MorphoSys sites, laying off 330. SiteOne Therapeutics secures $100M for non-opioid pain drugs. Novo Nordisk's obesity drug underperforms. Bristol Myers Squibb invests $100M in BioArctic's Alzheimer antibodies. Sudan's healthcare collapses. Tonix Pharmaceuticals files NDA for fibromyalgia drug. Neurocrine Biosciences wins FDA approval for Crenessity. Edgewise Therapeutics discusses accelerated approval for Becker muscular dystrophy. FDA places partial hold on PepGen's Duchenne therapy. Checkpoint Therapeutics' immunotherapy approved. WHO opens Academy in Lyon. GSK's Jemperli earns FDA Breakthrough status. Sanofi's duvakitug shows remission in ulcerative colitis. Sandoz agrees to $275M settlement over drug pricing. Pfizer projects 2025 earnings. Mesoblast's Ryoncil approved as 1st MSC therapy for graft-vs-host disease.

FDA placed a clinical hold on PepGen's phase 2 CONNECT2-EDO51 study for Duchenne muscular dystrophy. Edgewise Therapeutics reported positive phase 2 CANYON trial results for sevasemten in Becker muscular dystrophy. Sanofi's tolebrutinib received breakthrough therapy designation for non-relapsing secondary progressive multiple sclerosis.

Sorriso Pharmaceuticals' Phase Ib trial of SOR102, an oral drug for ulcerative colitis, met its endpoints, showing safety, tolerability, and significant clinical improvements. The company plans to advance to Phase II trials in 2025.

The 'Meningitis - Global Clinical Trials Review, 2024' report by ResearchAndMarkets.com offers an overview of meningitis clinical trials, including trial numbers, enrollment, regions, countries, phases, statuses, and sponsor types. It highlights prominent drugs and companies involved, providing insights into global clinical trials landscape and enrollment trends.

Innovent Biologics announced China's NMPA approval of DOVBLERON®, a next-gen ROS1 TKI for previously treated ROS1-positive NSCLC. DOVBLERON®, Innovent's 13th commercial product, addresses unmet needs, especially for patients with brain metastases and resistance to prior ROS1 TKIs. A second NDA for DOVBLERON® was accepted for ROS1-positive NSCLC patients without prior ROS1 TKI treatment.

Sanofi acquires exclusive rights to develop and commercialize aficamten, a next-in-class cardiac myosin inhibitor for hypertrophic cardiomyopathy in Greater China from Corxel Pharmaceuticals. Cytokinetics remains eligible for up to $150 million in milestone payments and royalties on future sales. Aficamten has received Breakthrough Therapy Designation for symptomatic obstructive hypertrophic cardiomyopathy and is under various clinical trials.